Earnings Call · Q3 FY2023·2023-08-07

Q3 23EPS +15.07%·Rev n/aQ2 23EPS +7.25%·Rev n/aQ1 23EPS +13.13%·Rev n/aQ4 22EPS +5.93%·Rev n/a⚠ consensus missing

ENANTA PHARMACEUTICALS INC ENTA

Jennifer Viera — Investor Relations or Communications

Jay Luly — President and Chief Executive Officer

Paul Mellett — Chief Financial Officer

−4.2%1d on move date−3.8% vs SPY3d−15.2%5d−18.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ENTA calls or request research access.

More ENTA calls Browse calls Request research access